| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-04-12 | HMPL-689 | 1 | Hutchison China MediTech Limited (China) | Cancer - Oncology | |
| 2016-04-12 | AB-PA01 (Pseudomonas aeruginosa bacteriophages) | Pseudomonas aeruginosa infections in cystic fibrosis patients | preclinical | AmpliPhi BioSciences (USA - VA) | Infectious diseases - Rare diseases |
| 2016-04-11 | dipraglurant (ADX48621) | levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients | 1 | Addex Therapeutics (Switzerland) Johns Hopkins University (USA - MD) | Neurodegenerative diseases |
| 2016-04-11 | brigatinib (AP26113) | ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor | 3 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2016-04-11 | Epidiolex® (cannabidiol (2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) | tuberous sclerosis complex | 3 | GW Pharmaceuticals (UK) | Cancer - Oncology - Rare diseases |
| 2016-04-11 | lefamulin (BC 3781) | community-acquired bacterial pneumonia | 3 | Nabriva Therapeutics (Austria) | Infectious diseases |
| 2016-04-11 | Epicutaneous Immunotherapy (EPIT), oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) | peanut allergy | preclinical | DBV Technologies (France) | Allergic diseases |
| 2016-04-08 | AZD3293/LY3314814 | Alzheimer´s disease | 2-3 | AstraZeneca (UK) Eli Lilly (USA - IN) | Neurodegenerative diseases |
| 2016-04-07 | CVT 301 (levodopa inhalation powder) | idiopathic Parkinson's disease | 3 | Acorda Therapeutics (USA - NY) | Neurodegenerative diseases |
| 2016-04-07 | MOR106 | inflammation | 1 | Galapagos (Belgium) Morphosys (Germany) | Inflammatory diseases |
| 2016-04-07 | trofinetide - NNZ-2566 - glycyl-L-2-methylprolyl-L-glutamic acid | Rett syndrome | 2 | Neuren Pharmaceuticals (Australia) | Rare diseases |
| 2016-04-07 | MVX-ONCO-1 | solid tumors | 1 | Maxivax (Switzerland) | Cancer - Oncology |
| 2016-04-06 | BIND-014 (docetaxel encapsulated in a polymeric nanoparticle) | urothelial carcinoma, cholangiocarcinoma, cervical cancer, squamous cell carcinoma of head and neck | 2 | Bind Therapeutics (USA - MA) | Cancer - Oncology |
| 2016-04-06 | BIND-014 (docetaxel encapsulated in a polymeric nanoparticle) | non-small cell lung cancer (NSCLC) | 2 | Bind Therapeutics (USA - MA) | Cancer - Oncology |
| 2016-04-06 | GLPG1690 | idiopathic pulmonary fibrosis | 2a | Galapagos (Belgium) | Lung diseases - Respiratory diseases - Rare diseases |
| 2016-04-06 | MOR208 and lenalidomide | relapsed or refractory diffuse large B cell lymphoma (DLBCL) | 2 | MorphoSys (Germany) | Cancer - Oncology |
| 2016-04-05 | Atu027 and gemcitabine | pancreatic cancer | 1b-2a | Silence Therapeutics (UK) | Cancer - Oncology |
| 2016-04-05 | BI 1026706 | macular edema | 2 | Boehringer Ingelheim (Germany) | Ophtalmological diseases |
| 2016-04-04 | ORY-2001 | Alzheimer's disease | 1 | Oryzon Genomics (Spain) | Neurodegenerative diseases |
| 2016-04-04 | masitinib | amyotrophic lateral sclerosis (ALS) | 3 | AB Science (France) | Neurodegenerative diseases - Rare diseases |
